ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Liver Enzyme Elevations Fly In Ointment?
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.
